129 results on '"Vassal G."'
Search Results
2. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
3. Joint adolescent–adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform—ACCELERATE
4. Nouveaux médicaments contre les cancers pédiatriques : ce qui doit bouger en Europe
5. Multidisciplinarité et formation des spécialistes à l’oncologie et à l’hématologie maligne pédiatrique
6. Accès aux essais précoces de nouveaux médicaments anticancéreux pour les enfants et les adolescents en France
7. Actualités pharmacologiques – le crizotinib (Xalkori®)
8. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial
9. Dose-finding designs in pediatric phase I clinical trials: Comparison by simulations in a realistic timeline framework
10. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper
11. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy
12. More and better cure for an orphan: priorities for future paediatric cancer research in Europe – Meeting report of the EC-funded science-communication project DIRECT “Overcoming Cancer with Research”
13. Imperative of continual support by the European Community for future advances in paediatric oncology in Europe: meeting report of the EC-funded science-communication project DIRECT “Overcoming Cancer with Research”
14. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring
15. Pleiotrophin, a candidate gene for poor tumor vasculature and in vivo neuroblastoma sensitivity to irinotecan
16. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa)
17. Human growth hormone gene transfer into tumor cells may improve cancer chemotherapy
18. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma
19. Thérapies ciblées en oncologie pédiatrique : nouvelle approche thérapeutique
20. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma
21. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution
22. Elevated Plasma Ferritin and Busulfan Pharmacodynamics During High-dose Chemotherapy Regimens in Children with Malignant Solid Tumors
23. European collaboration in trials of new agents for children with cancer
24. AcSé crizotinib, un essai pionnier du programme AcSé dans le champ de la médecine personnalisée (in partie IV : Soutenir l’innovation scientifique en cancérologie)
25. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma
26. Brain tumours under the age of three. The price of survival: A retrospective study of 20 long-term survivors
27. Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma
28. Individual dosing of carboplatin based on drug monitoring in children receiving high-dose chemotherapy
29. Autorisation de mise sur le marché et information pédiatrique pour les médicaments de chimiothérapie des cancers : état des lieux et propositions
30. Quoi de neuf en oncologie pédiatrique
31. Pharmacokinetics of high-dose busulfan in children
32. Enhanced cutaneous radiation effects following high-dose busulfan therapy
33. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG)
34. Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies.
35. A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours.
36. Dose finding and O6-alkylguanine-DNA alkyltransferase study of cisplatin combined with temozolomide in paediatric solid malignancies.
37. No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
38. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
39. Outcome of flat bone sarcomas (other than Ewing's) in children and adolescents: a study of 25 cases.
40. Potentiation of tumour apoptosis by human growth hormone via glutathione production and decreased NF-kappaB activity.
41. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts.
42. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma.
43. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study.
44. p53-dependent G2 arrest associated with a decrease in cyclins A2 and B1 levels in a human carcinoma cell line.
45. Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.
46. Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children.
47. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
48. Cerebrospinal Fluid and Plasma Methotrexate Levels Following High-Dose Regimen Given as a 3-Hour Intravenous Infusion in Children with Nonhodgkin's Lymphoma.
49. OA12.03 Activity of Crizotinib in MET or ROS1 Positive (+) NSCLC: Results of the AcSé Trial.
50. 596 POSTER The topoisomerase I inhibitor gimatecan exhibits synergistic activity with temozolomide and tyrosine kinase inhibitors in malignant glioma xenografts.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.